- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers
Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses the phase 2 LIO-1 trial (NCT04042116) evaluation of lucitanib and nivolumab (Opdivo) across different gynecologic cancer subtypes.
The phase 2 portion of the LIO-1 trial will examine the combination in several gynecologic cohorts, according to Hamilton. These cohorts include patients with ovarian cancer, endometrial cancer, and cervical cancer, with a fourth cohort examining the combination in patients with clear cell cancer, of either endometrial or ovarian origin. Investigators will begin with a 6-mg dose and increase to 8 mg and 10 mg, as tolerated by patients, Hamilton concludes.
Related Content:
